These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38621924)

  • 21. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver cirrhosis and immune dysfunction.
    Hasa E; Hartmann P; Schnabl B
    Int Immunol; 2022 Sep; 34(9):455-466. PubMed ID: 35792761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
    Fortea JI; Zipprich A; Fernandez-Mena C; Puerto M; Bosoi CR; Almagro J; Hollenbach M; Bañares J; Rodríguez-Sánchez B; Cercenado E; Clément MA; Rose CF; Bañares R; Vaquero J; Ripoll C
    Liver Int; 2018 Jan; 38(1):102-112. PubMed ID: 28665498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
    Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis.
    Gómez-Hurtado I; Santacruz A; Peiró G; Zapater P; Gutiérrez A; Pérez-Mateo M; Sanz Y; Francés R
    PLoS One; 2011; 6(7):e23037. PubMed ID: 21829583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norfloxacin is more effective than Rifaximin in avoiding bacterial translocation in an animal model of cirrhosis.
    Gómez-Hurtado I; Gimenez P; García I; Zapater P; Francés R; González-Navajas JM; Manichanh C; Ramos JM; Bellot P; Guarner F; Such J
    Liver Int; 2018 Feb; 38(2):295-302. PubMed ID: 28834270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis.
    Moratalla A; Gómez-Hurtado I; Moya-Pérez Á; Zapater P; Peiró G; González-Navajas JM; Gómez Del Pulgar EM; Such J; Sanz Y; Francés R
    Eur J Nutr; 2016 Feb; 55(1):197-206. PubMed ID: 25657013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of the Gut Microbiome in Liver Cirrhosis Treatment.
    Lee NY; Suk KT
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF.
    Moreau R; Clària J; Aguilar F; Fenaille F; Lozano JJ; Junot C; Colsch B; Caraceni P; Trebicka J; Pavesi M; Alessandria C; Nevens F; Saliba F; Welzel TM; Albillos A; Gustot T; Fernández J; Moreno C; Baldassarre M; Zaccherini G; Piano S; Montagnese S; Vargas V; Genescà J; Solà E; Bernal W; Butin N; Hautbergue T; Cholet S; Castelli F; Jansen C; Steib C; Campion D; Mookerjee R; Rodríguez-Gandía M; Soriano G; Durand F; Benten D; Bañares R; Stauber RE; Gronbaek H; Coenraad MJ; Ginès P; Gerbes A; Jalan R; Bernardi M; Arroyo V; Angeli P; ; ;
    J Hepatol; 2020 Apr; 72(4):688-701. PubMed ID: 31778751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF.
    Vairappan B; Wright G; M S; Ravikumar TS
    Eur J Pharmacol; 2023 Nov; 958():176010. PubMed ID: 37634841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure.
    Kim SE; Park JW; Kim HS; Jang MK; Suk KT; Kim DJ
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis.
    Horvatits T; Drolz A; Roedl K; Rutter K; Ferlitsch A; Fauler G; Trauner M; Fuhrmann V
    Liver Int; 2017 Feb; 37(2):224-231. PubMed ID: 27416294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis.
    Moratalla A; Gómez-Hurtado I; Santacruz A; Moya Á; Peiró G; Zapater P; González-Navajas JM; Giménez P; Such J; Sanz Y; Francés R
    Liver Int; 2014 Jul; 34(6):850-8. PubMed ID: 24267920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.
    Xiang X; Feng D; Hwang S; Ren T; Wang X; Trojnar E; Matyas C; Mo R; Shang D; He Y; Seo W; Shah VH; Pacher P; Xie Q; Gao B
    J Hepatol; 2020 Apr; 72(4):736-745. PubMed ID: 31786256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new model of portal vein thrombosis in rats with cirrhosis induced by partial portal vein ligation plus carbon tetrachloride and intervened with rivaroxaban.
    Guo Y; Dong S; Li M; Tao Y; Lv J; Liu C
    BMC Gastroenterol; 2024 May; 24(1):161. PubMed ID: 38741060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    Trebicka J; Fernandez J; Papp M; Caraceni P; Laleman W; Gambino C; Giovo I; Uschner FE; Jansen C; Jimenez C; Mookerjee R; Gustot T; Albillos A; Bañares R; Jarcuska P; Steib C; Reiberger T; Acevedo J; Gatti P; Shawcross DL; Zeuzem S; Zipprich A; Piano S; Berg T; Bruns T; Danielsen KV; Coenraad M; Merli M; Stauber R; Zoller H; Ramos JP; Solé C; Soriano G; de Gottardi A; Gronbaek H; Saliba F; Trautwein C; Kani HT; Francque S; Ryder S; Nahon P; Romero-Gomez M; Van Vlierberghe H; Francoz C; Manns M; Garcia-Lopez E; Tufoni M; Amoros A; Pavesi M; Sanchez C; Praktiknjo M; Curto A; Pitarch C; Putignano A; Moreno E; Bernal W; Aguilar F; Clària J; Ponzo P; Vitalis Z; Zaccherini G; Balogh B; Gerbes A; Vargas V; Alessandria C; Bernardi M; Ginès P; Moreau R; Angeli P; Jalan R; Arroyo V;
    J Hepatol; 2021 May; 74(5):1097-1108. PubMed ID: 33227350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.
    Sundaram V; Jalan R; Ahn JC; Charlton MR; Goldberg DS; Karvellas CJ; Noureddin M; Wong RJ
    J Hepatol; 2018 Sep; 69(3):617-625. PubMed ID: 29709681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating microbiome in patients with portal hypertension.
    Gedgaudas R; Bajaj JS; Skieceviciene J; Varkalaite G; Jurkeviciute G; Gelman S; Valantiene I; Zykus R; Pranculis A; Bang C; Franke A; Schramm C; Kupcinskas J
    Gut Microbes; 2022; 14(1):2029674. PubMed ID: 35130114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis.
    Sánchez E; Nieto JC; Boullosa A; Vidal S; Sancho FJ; Rossi G; Sancho-Bru P; Oms R; Mirelis B; Juárez C; Guarner C; Soriano G
    Liver Int; 2015 Mar; 35(3):735-45. PubMed ID: 24750552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.